NeuroEndocrine Cancer Australia unveils new website and digital lifeline
NeuroEndocrine Cancer Australia (NECA) has launched a fully updated digital platform designed to improve how the 31,000 Australians affected by neuroendocrine cancer (NETs) access support, information, and specialist care. SYDNEY, May 15, 2026 /PRNewswire/ -- The new website introduces a personalised patient hub experience aimed at helping people navigate every stage of the NET journey, from diagnosis through to...
POMDOCTOR LIMITED Announces Fiscal Year 2025 Financial Results
GUANGZHOU, China, May 15, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced its financial results for the fiscal year ended December 31, 2025. Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "Fiscal year 2025 marked a year of solid revenue expansion...
DeepQure Reports Encouraging Clinical Data from World’s First Extravascular RDN System at AUA 2026
WASHINGTON, May 15, 2026 /PRNewswire/ -- DeepQure, a clinical-stage medical device company, announced the completion of its featured presentation at the American Urological Association (AUA) Innovation Nexus Forum, held during the AUA Annual Meeting. DeepQure was selected to present the clinical progress of HyperQure™, the world's first minimally invasive (laparoscopic/robotic) extravascular renal denervation (RDN) system. The Innovation Nexus...
Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Level Evidence NASHIK, India, May 14, 2026 /PRNewswire/ -- Datar Cancer Genetics (DCG), a global precision oncology company, today announced that its tissue-based comprehensive genomic profiling (CGP) assay for all solid tumors, CellDx-Tissue, has been cleared by the US...
Frost & Sullivan Institute Highlights Global Impact Through Visionary Leadership Best Practices Recognition, 2026
SAN ANTONIO, May 14, 2026 /PRNewswire/ -- The Frost & Sullivan Institute (FSI) is proud to announce the latest cohort of honorees for its Visionary Leadership Best Practices Recognition, 2026. This prestigious accolade is reserved for those leaders who transcend traditional business metrics to prioritize humanity, sustainability, and global equity. The Frost & Sullivan Institute Best Practices Recognition is...
CHEPLAPHARM to Accelerate Global Supply Chain Digitalization with TraceLink MINT
The German pharmaceutical company unifies its digital partner network, laying the foundation for AI-driven supply chain orchestration BOSTON, May 14, 2026 /PRNewswire/ -- TraceLink, the world's largest Agentic Business Network, today announced that the German-based but globally active CHEPLAPHARM Group, a world leader in the acquisition of original preparations from the...
Yuyu Pharma’s Mervyn’s Petcare Launches Cat Dental Care Treat on Amazon, Marking First Overseas Pet Health Push
SEOUL, South Korea, May 14, 2026 /PRNewswire/ -- Mervyn's Petcare, the U.S. subsidiary of Korea-based Yuyu Pharmaceutical (KRX: 000220), has launched its first cat dental care nutritional supplement product, "Ari's Purrfect Dental Bites," on Amazon. This launch marks the company's initial foray into the U.S. pet health market and a significant milestone in...
OnCusp Therapeutics Appoints Anthony Kim as Chief Financial Officer
PRINCETON, N.J., May 14, 2026 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company developing differentiated oncology therapies designed to translate cutting-edge innovation into clinically meaningful outcomes for patients, today announced the appointment of Anthony Kim as Chief Financial Officer. Mr. Kim is a seasoned finance executive with more than 25 years of experience spanning biotechnology leadership and global...
China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
HAIKOU, China, May 14, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on May 12 and 13, the NYSE American has contacted the Company in accordance with its...
Origin Agritech to Hold Business Update & First Half Fiscal Year 2026 Earnings Conference Call on May 22 at 8 a.m. ET
BEIJING, May 14, 2026 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, will announce its financial results for the first half of fiscal year 2026 on Thursday, May 21. Origin will host a conference call on Friday, May 22, at 8 a.m. ET with the investment community to discuss the...
